<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922441</url>
  </required_header>
  <id_info>
    <org_study_id>A657-BR-CT-203</org_study_id>
    <nct_id>NCT00922441</nct_id>
  </id_info>
  <brief_title>A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Valsartan-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan(BR-A-657•K) During 24hours by Dose in Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antihypertensive efficacy and safety of
      Fimasartan (BR-A-657•K) during 24 hours by dose in patients with mild to moderate essential
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fimasartan(BR-A-657-K), a selective blocker of AT1 receptor subtype, showed the rapid and
      potent antihypertensive effect in many hypertensive models. Phase I study,
      Fimasartan(BR-A-657-K) 20mg ~ 480mg single dosing with healthy subjects, demonstrated that
      the Fimasartan(BR-A-657-K) was very safe and well tolerated. Another phase I study,
      Fimasartan(BR-A-657-K) 120mg and 360mg dosing for 7 days, also showed that
      Fimasartan(BR-A-657-K) was safe and tolerable though one temporal adverse event was observed
      in high dose.

      A Randomized, Double-blind, Valsartan-referenced, Parallel Grouped, Therapeutic Exploratory
      Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan(BR-A-657•K) during
      24hoursby dose in Patients with Mild to Moderate Essential Hypertension.

      Approximately 90 patients will be enrolled over 12 months in 5 centers nationwide.

      After 2 weeks of placebo run-in period, all subjects will be randomized into one of the
      following 3 groups. Subjects will take test/control drug for 8 weeks of treatment period.

      If subjects take any antihypertensive medications before screening, the subjects will have 1
      week of wash-out period.

      Group I : Fimasartan 60mg group. Group II : Fimasartan 120mg group Group III : Valsartan 80mg
      group
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change of Diastolic Blood Pressure</measure>
    <time_frame>baseline and 8 Weeks</time_frame>
    <description>24hr Mean change of DBP on Week 8, from Baseline</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Fimasartan 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimasartan 60 mg group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimasartan 120 mg group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference (Valsartan 80 mg) group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan 60 mg group</intervention_name>
    <description>Fimasartan 60 mg</description>
    <arm_group_label>Fimasartan 1</arm_group_label>
    <other_name>BR-A-657.K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan 120 mg group</intervention_name>
    <description>Fimasartan 120 mg</description>
    <arm_group_label>Fimasartan 2</arm_group_label>
    <other_name>BR-A-657.K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference (Valsartan 80 mg) group</intervention_name>
    <description>Reference (Valsartan 80 mg)</description>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate essential hypertension : sitting diastolic blood pressure measured at
             Placebo visit and Baseline are 90~109mmHg inclusive and the difference between sitting
             diastolic blood pressures measured at Placebo visit and Baseline(Day0) is under 7mmHg.

          -  Subjects who agree to participate in this sudy and give written informed consent

          -  Subjects considered to understand the study, be cooperative, and able to be
             followed-up until the end of the study

        Exclusion Criteria:

          -  The sitting DBP is less than 89mmHg or more than 110mmHg or severe hypertensive
             patient with sitting systolic blood pressure over 200mmHg Patients with secondary
             hypertension

          -  Patients with severe renal(Creatinine more 1.5mg/dl), gastrointestinal, hematological
             or hepatic(AST, ALT more 2 twice more than upper limit of normal)disease etc. which
             might affect absorption, disposition, metabolism or excretion of the drug

          -  Patients with postural hypotension

          -  Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes
             mellitus(HbA1c&gt;9%, regimen change of oral hypoglycemic agents within 12weeks, treated
             insulin before screening)

          -  Patients with a history of myocardial infarction, severe coronary artery disease or
             clinically significant heart failure or valvular defect in last 6 months

          -  Patients with consumptive disease, autoimmune disease, connective tissue disease

          -  Patients with a history of type B or C hepatitis

          -  Patients with HIV or hepatitis

          -  Patients with clinically significant laboratory abnormality

          -  Patients receiving any drugs known to affect blood pressure or medical treatments that
             can influence the blood pressure

          -  Patients with allergy or contraindication to any angiotensin II receptor antagonists

          -  Female of childbearing potential who does not undergo hysterectomy or is not
             post-menopausal

          -  Patients judged to have a history of alcohol or drug abuse by the investigator

          -  Patients participated other clinical trial 12 weeks before Screening Patients judged
             to be inappropriate for this study by the investigator with other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-He Oh, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Soo Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung Chul Chae, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gi-Sik Kim, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daegu Catholic University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung-Ho Jung, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Connam National University Hospital</affiliation>
  </overall_official>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <results_first_submitted>January 16, 2018</results_first_submitted>
  <results_first_submitted_qc>January 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2018</results_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <keyword>Essential Hypertension</keyword>
  <keyword>24hour ABPM</keyword>
  <keyword>Population PK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fimasartan 1</title>
          <description>Fimasartan 60 mg group
Fimasartan 60 mg daily, po</description>
        </group>
        <group group_id="P2">
          <title>Fimasartan 2</title>
          <description>Fimasartan 120 mg group
Fimasartan 120 mg daily, po</description>
        </group>
        <group group_id="P3">
          <title>Valsartan: Control</title>
          <description>Reference (Valsartan 80 mg) group
Valsartan 80 mg daily, po</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fimasartan 1</title>
          <description>Fimasartan 60 mg group
Fimasartan 60 mg daily, po</description>
        </group>
        <group group_id="B2">
          <title>Fimasartan 2</title>
          <description>Fimasartan 120 mg group
Fimasartan 120 mg daily, po</description>
        </group>
        <group group_id="B3">
          <title>Valsartan: Control</title>
          <description>Reference (Valsartan 80 mg) group
Valsartan 80 mg daily, po</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.07" spread="8.36"/>
                    <measurement group_id="B2" value="54.07" spread="8.79"/>
                    <measurement group_id="B3" value="56.00" spread="7.15"/>
                    <measurement group_id="B4" value="54.09" spread="8.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change of Diastolic Blood Pressure</title>
        <description>24hr Mean change of DBP on Week 8, from Baseline</description>
        <time_frame>baseline and 8 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fimasartan 1-ITT</title>
            <description>Fimasartan 60 mg group
Fimasartan 60 mg daily, po</description>
          </group>
          <group group_id="O2">
            <title>Fimasartan 2-ITT</title>
            <description>Fimasartan 120 mg group
Fimasartan 120 mg daily, po</description>
          </group>
          <group group_id="O3">
            <title>Valsartan: Control-ITT</title>
            <description>Reference (Valsartan 80 mg) group
Valsartan 80 mg daily, po</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of Diastolic Blood Pressure</title>
          <description>24hr Mean change of DBP on Week 8, from Baseline</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.15" spread="5.94"/>
                    <measurement group_id="O2" value="-7.19" spread="9.51"/>
                    <measurement group_id="O3" value="-6.70" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Efficacy, Safety</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>comparison between the groups</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fimasartan 1</title>
          <description>Fimasartan 60 mg group
Fimasartan 60 mg daily, po</description>
        </group>
        <group group_id="E2">
          <title>Fimasartan 2</title>
          <description>Fimasartan 120 mg group
Fimasartan 120 mg daily, po</description>
        </group>
        <group group_id="E3">
          <title>Valsartan: Control</title>
          <description>Reference (Valsartan 80 mg) group
Valsartan 80 mg daily, po</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager of Clinical Research</name_or_title>
      <organization>Boryung Pharmaceutical</organization>
      <phone>+82-2-708-8069</phone>
      <email>rainbowleo@boryung.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

